Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Equity Ratio (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Equity Ratio data on record, last reported at 0.54 in Q3 2025.

  • For Q3 2025, Equity Ratio fell 13.15% year-over-year to 0.54; the TTM value through Sep 2025 reached 0.54, down 13.15%, while the annual FY2024 figure was 0.61, 10.43% down from the prior year.
  • Equity Ratio reached 0.54 in Q3 2025 per GANX's latest filing, up from 0.38 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.93 in Q1 2021 and bottomed at 0.38 in Q2 2025.
  • Average Equity Ratio over 5 years is 0.7, with a median of 0.68 recorded in 2023.
  • Peak YoY movement for Equity Ratio: skyrocketed 38.3% in 2021, then plummeted 38.78% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.89 in 2021, then decreased by 12.28% to 0.78 in 2022, then dropped by 13.72% to 0.68 in 2023, then decreased by 10.43% to 0.61 in 2024, then decreased by 11.03% to 0.54 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.54 in Q3 2025, 0.38 in Q2 2025, and 0.5 in Q1 2025.